AU Stock MarketDetailed Quotes

MSB Mesoblast Ltd

Watchlist
  • 2.800
  • -0.100-3.45%
20min DelayMarket Closed Feb 14 16:00 AET
3.57BMarket Cap-0.21P/E (Static)

Mesoblast Ltd Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Mesoblast Ltd Q2 2025 Estimates Date

Currency：AUDFeb 27, 2025

Estimate YoY
Revenue
2.49M
-52.31%
EPS
-0.06
--
Analyst Rating
Strong Buy

Jan 20, 2025

Mesoblast Ltd Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: AUD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
Feb 27, 20252025/Q2-- / 2.489M--
--2025/Q1-- / 2.385M--
Aug 29, 20242024/Q4-- / 6.612M--
--2024/Q3-- / 0.000--
Feb 29, 20242024/Q25.219M / 5.761M--
DatePeriodRevenue/EstimateEarnings Call
Feb 27, 20252025/Q2-- / 2.489M--
--2025/Q1-- / 2.385M--
Aug 29, 20242024/Q4-- / 6.612M--
--2024/Q3-- / 0.000--
Feb 29, 20242024/Q25.219M / 5.761M--

Unlock Free Earnings Estimates

Mesoblast Ltd Earnings Reports

  • Mesoblast Ltd: Annual Report to Shareholders

    Oct 16, 2024 22:29 ET

  • Mesoblast Ltd: Annual Financial Results Presentation

    Aug 28, 2024 18:13 ET

  • Mesoblast Ltd: Preliminary Final Report including Appendix 4E

    Aug 28, 2024 18:01 ET

  • Mesoblast Ltd: MSB Q2 Financial Results and Operational Highlights

    Feb 28, 2024 16:54 ET

    • Read more

    Trending Stocks
    ASX High Dividend ASX High Dividend
    Symbol Div YieldTTM Dividend TTM
    Origin Energy Ltd
    ORG
    4.60% 0.48
    Rio Tinto Ltd
    RIO
    5.25% 6.36
    Telstra Group Ltd
    TLS
    4.50% 0.18
    Westpac Banking Corp
    WBC
    4.24% 1.47
    ANZ Group Holdings Ltd
    ANZ
    5.66% 1.77

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Jan 20, 2025

    Strong Buy

    • Strong Buy

      75.00%

    • Buy

      0.00%

    • Hold

      25.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Investment Theme Healthcare - Cancer Research
    Healthcare - Cancer Research
    Intraday+0.95%